FTI Survey: US Healthcare & Life Sciences Industry Outlook 2022Download a PDF of this article
As we emerge from the COVID-19 pandemic, we conducted our second annual FTI Consulting Survey: US Healthcare & Life Sciences Industry Outlook, asking industry leaders about key topics and trends ahead of the sector’s largest summit, the J.P. Morgan Healthcare Conference (#JPM2022).
New ways of working, connecting, and doing business have inevitably emerged from major disruption across industries and geographies in the past two years. The healthcare and life sciences industry has seen its reputation significantly improve during the pandemic, and special purpose acquisition companies (SPACs), discourse around diversity, equity, & inclusion, and virtual gatherings have become essential threads in the fabric of modern society.
In October 2021, FTI conducted its annual survey of 251 senior decision makers working in corporate
communications, investor relations, public affairs, business development, R&D and marketing for healthcare and life sciences companies in the U.S. to understand how the industry’s perspective has evolved since 2020. More than half of respondents represent large companies, and a third represent publicly listed companies with an average $5.8 billion market cap. The survey tracks opinions around virtual conferences anticipated in 2022, as well as M&A, IPO, and SPAC activity in the sector. It also includes perceived risks and levels of preparedness, and themes that surfaced in the last year, including the political & regulatory environment
and diversity & inclusion.
For full survey findings and recommendations from our team of strategic communications experts on how to maximize your time during #JPM22, download the full report below.
Our survey findings reveal that the reputation and outlook of the industry remains positive, with nearly 7 in 10 survey respondents (69%) believing that the reputation of the healthcare and life sciences industry has improved over the last 12 months and 53% of survey respondents thinking potential Congressional Action on the industry could have a positive impact.
Additionally, our survey results show that COVID-19, economic & political uncertainty, and talent scarcity are seen as the biggest risks and companies are still not fully prepared to respond. Survey respondents believe that out of the four key risks identified, the two biggest risks for companies are economic uncertainty (81%) and talent scarcity (78%).